Pharmacologic Treatment of Cancer-Related Fatigue

  • Carroll J
  • Kohli S
  • Mustian K
  • et al.
88Citations
Citations of this article
117Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Fatigue is the most commonly reported symptom in patients with cancer, with a prevalence of over 60% reported in the majority of studies. This paper systematically reviews pharmacologic agents in the treatment of cancer-related fatigue (CRF). We conducted a literature review of clinical trials that assessed pharmacologic agents for the treatment of CRF. These agents include hematopoietics (for anemia), corticosteroids, and psychostimulants. Other therapeutic agents that are less well studied for CRF but are currently the focus of clinical trials include l-carnitine, modafinil, bupropion, and selective serotonin reuptake inhibitors such as paroxetine.Disclosure of potential conflicts of interest is found at the end of this article.

Cite

CITATION STYLE

APA

Carroll, J. K., Kohli, S., Mustian, K. M., Roscoe, J. A., & Morrow, G. R. (2007). Pharmacologic Treatment of Cancer-Related Fatigue. The Oncologist, 12(S1), 43–51. https://doi.org/10.1634/theoncologist.12-s1-43

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free